Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data.

ABSTRACT:

Background

Early-phase clinical trials of protein arginine methyltransferase 5 (PRMT5) inhibitors as synthetic lethal strategies have shown promising efficacy in methylthioadenosine phosphorylase (MTAP)-deleted tumors. To refine and expand this promising therapeutic approach within the framework of precision oncology, it is critical to comprehensively characterize the clinical and molecular profiles of MTAP-deleted tumors.

Materials and methods

This pan-cancer retrospective cohort study analyzed clinico-genomic data from the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, which includes 99.7% of patients who underwent comprehensive genomic profiling (CGP) in Japan between June 2019 and November 2023. Machine learning and explainable artificial intellig

SUBMITTER: Ikushima H 

PROVIDER: S-EPMC11985008 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature